Faster access than browser!
20 relations: Binimetinib, BRAF (gene), Clinical trial, Cobimetinib, Colorectal cancer, Dabrafenib, KRAS, MAP2K1, MAP2K2, MAPK/ERK pathway, MEK inhibitor, Melanoma, Mitogen-activated protein kinase kinase, Multiple myeloma, Neuroblastoma RAS viral oncogene homolog, Non-small-cell lung carcinoma, Ovarian cancer, Selumetinib, Trametinib, Vemurafenib.
Binimetinib
Binimetinib (MEK162, ARRY-162) is a MEK inhibitor being developed by Array Biopharma to treat various cancers.
New!!: MEK inhibitor and Binimetinib · See more »
BRAF (gene)
BRAF is a human gene that encodes a protein called B-Raf.
New!!: MEK inhibitor and BRAF (gene) · See more »
Clinical trial
Clinical trials are experiments or observations done in clinical research.
New!!: MEK inhibitor and Clinical trial · See more »
Cobimetinib
Cobimetinib (trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech (Roche).
New!!: MEK inhibitor and Cobimetinib · See more »
Colorectal cancer
Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine).
New!!: MEK inhibitor and Colorectal cancer · See more »
Dabrafenib
Dabrafenib (trade name Tafinlar, GSK2118436) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF.
New!!: MEK inhibitor and Dabrafenib · See more »
KRAS
KRAS (K-ras or Ki-ras) is a gene that acts as an on/off switch in cell signalling.
New!!: MEK inhibitor and KRAS · See more »
MAP2K1
Dual specificity mitogen-activated protein kinase kinase 1 is an enzyme that in humans is encoded by the MAP2K1 gene.
New!!: MEK inhibitor and MAP2K1 · See more »
MAP2K2
Dual specificity mitogen-activated protein kinase kinase 2 is an enzyme that in humans is encoded by the MAP2K2 gene.
New!!: MEK inhibitor and MAP2K2 · See more »
MAPK/ERK pathway
The MAPK/ERK pathway (also known as the Ras-Raf-MEK-ERK pathway) is a chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell.
New!!: MEK inhibitor and MAPK/ERK pathway · See more »
MEK inhibitor
A MEK inhibitor is a chemical or drug that inhibits the mitogen-activated protein kinase kinase enzymes MEK1 and/or MEK2.
New!!: MEK inhibitor and MEK inhibitor · See more »
Melanoma
Melanoma, also known as malignant melanoma, is a type of cancer that develops from the pigment-containing cells known as melanocytes.
New!!: MEK inhibitor and Melanoma · See more »
Mitogen-activated protein kinase kinase
Mitogen-activated protein kinase kinase (also known as MAP2K, MEK, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).
New!!: MEK inhibitor and Mitogen-activated protein kinase kinase · See more »
Multiple myeloma
Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies.
New!!: MEK inhibitor and Multiple myeloma · See more »
Neuroblastoma RAS viral oncogene homolog
NRAS is an enzyme that in humans is encoded by the NRAS gene.
New!!: MEK inhibitor and Neuroblastoma RAS viral oncogene homolog · See more »
Non-small-cell lung carcinoma
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC).
New!!: MEK inhibitor and Non-small-cell lung carcinoma · See more »
Ovarian cancer
Ovarian cancer is a cancer that forms in or on an ovary.
New!!: MEK inhibitor and Ovarian cancer · See more »
Selumetinib
Selumetinib (AZD6244) is a drug that was discovered by Array BioPharma and was licensed to AstraZeneca.
New!!: MEK inhibitor and Selumetinib · See more »
Trametinib
Trametinib (trade name Mekinist) is a cancer drug.
New!!: MEK inhibitor and Trametinib · See more »
Vemurafenib
Vemurafenib (INN, marketed as Zelboraf) is a B-Raf enzyme inhibitor developed by Plexxikon (now part of Daiichi-Sankyo) and Genentech for the treatment of late-stage melanoma.
New!!: MEK inhibitor and Vemurafenib · See more »
